{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:33:12Z","timestamp":1791639192070,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112981","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:28:59Z","timestamp":1689078539000},"page":"112981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers"],"prefix":"10.1016","volume":"191","author":[{"given":"Edith","family":"Borcoman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lalanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0894","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-5508","authenticated-orcid":false,"given":"Jean-Marc","family":"Limacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Capitain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-7719","authenticated-orcid":false,"given":"Olivier","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ekwegbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4851-7450","authenticated-orcid":false,"given":"Emmanuelle","family":"Jeannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-5330","authenticated-orcid":false,"given":"Joanna","family":"Cyrta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Tran-Perennou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Castel-Ajgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-7777","authenticated-orcid":false,"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Brandely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Tavernaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Makhloufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9116","authenticated-orcid":false,"given":"Kaidre","family":"Bendjama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2023.112981_bib1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112981_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.112981_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0092-8674(91)90529-8","article-title":"Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation","volume":"67","author":"Crook","year":"1991","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ejca.2023.112981_bib4","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/j.1460-2075.1989.tb08594.x","article-title":"Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour suppressor gene product","volume":"8","author":"M\u00fcnger","year":"1989","journal-title":"EMBO J"},{"issue":"19","key":"10.1016\/j.ejca.2023.112981_bib5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10167","key":"10.1016\/j.ejca.2023.112981_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.ejca.2023.112981_bib7","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejca.2023.112981_bib8","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2023.112981_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.112981_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejca.2023.112981_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.ejca.2023.112981_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.112981_bib13","unstructured":"\u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bavencio-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.ejca.2023.112981_bib14","unstructured":"\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761049s006lbl.pdf\u3009."},{"issue":"2","key":"10.1016\/j.ejca.2023.112981_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112981_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-9904-0_10","article-title":"NanoString nCounter technology: high-throughput RNA validation","volume":"2079","author":"Goytain","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ejca.2023.112981_bib17","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1016\/j.annonc.2020.08.1031","article-title":"916MO safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent\/metastatic head and neck squamous cell carcinoma (HPV\u2009+\u2009R\/M HNSCC)","volume":"31","author":"Aggarwal","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.112981_bib18","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejca.2023.112981_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-017-0249-y","article-title":"Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade","volume":"5","author":"L\u00e4ubli","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.112981_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.112981_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002998","article-title":"Avelumab for platinum-ineligible\/refractory recurrent and\/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN solid tumour trial","volume":"9","author":"Guigay","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2023.112981_bib22","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.112981_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumour-specific vaccine for patients with incurable human papillomavirus 16\u2013Related cancer","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112981_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40268-021-00362-3","article-title":"Dissociated responses in patients with metastatic solid tumours treated with Immunotherapy","volume":"21","author":"Vaflard","year":"2021","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.ejca.2023.112981_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"52","key":"10.1016\/j.ejca.2023.112981_bib26","doi-asserted-by":"crossref","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112981_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Sch\u00fctz","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2023.112981_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejca.2023.112981_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","article-title":"The efficacy and safety of tipapkinogen sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase II trial with 2.5\u00a0years of follow-up","volume":"153","author":"Harper","year":"2019","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:57Z","timestamp":1760733717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S0959804923003337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112981","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112981"}}